Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.

Gutiérrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R.

Gut. 2014 Feb;63(2):272-80. doi: 10.1136/gutjnl-2012-303557. Epub 2013 Feb 1.

PMID:
23376290
2.

Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.

Juanola O, Moratalla A, Gutiérrez A, Sempere L, Zapater P, Giménez P, Almenta I, Peiró G, González-Navajas JM, Such JF, Francés R.

J Gastroenterol. 2015 Jul;50(7):758-68. doi: 10.1007/s00535-014-1020-5. Epub 2014 Dec 11.

PMID:
25500977
3.

Pattern recognition receptor and autophagy gene variants are associated with development of antimicrobial antibodies in Crohn's disease.

Murdoch TB, Xu W, Stempak JM, Landers C, Targan SR, Rotter JI, Silverberg MS.

Inflamm Bowel Dis. 2012 Sep;18(9):1743-8. doi: 10.1002/ibd.22884. Epub 2012 Jan 24.

4.

ATG16L1 and NOD2 polymorphisms enhance phagocytosis in monocytes of Crohn's disease patients.

Wolfkamp SC, Verseyden C, Vogels EW, Meisner S, Boonstra K, Peters CP, Stokkers PC, te Velde AA.

World J Gastroenterol. 2014 Mar 14;20(10):2664-72. doi: 10.3748/wjg.v20.i10.2664.

5.

Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.

Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN.

World J Gastroenterol. 2012 Sep 28;18(36):5058-64. doi: 10.3748/wjg.v18.i36.5058.

6.

ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis.

Homer CR, Richmond AL, Rebert NA, Achkar JP, McDonald C.

Gastroenterology. 2010 Nov;139(5):1630-41, 1641.e1-2. doi: 10.1053/j.gastro.2010.07.006. Epub 2010 Jul 14.

7.

Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype.

Gutiérrez A, Holler E, Zapater P, Sempere L, Jover R, Pérez-Mateo M, Schoelmerich J, Such J, Wiest R, Francés R.

Inflamm Bowel Dis. 2011 Aug;17(8):1641-50. doi: 10.1002/ibd.21537. Epub 2010 Nov 15.

PMID:
21744420
8.

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.

Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France..

Gastroenterology. 2002 Jul;123(1):106-11.

PMID:
12105838
9.

Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn's disease in Northern Europe.

Van Limbergen J, Russell RK, Nimmo ER, Drummond HE, Smith L, Anderson NH, Davies G, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Wilson DC, Satsangi J.

Inflamm Bowel Dis. 2008 Mar;14(3):338-46.

PMID:
18088053
10.

Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.

Włodarczyk M, Sobolewska A, Wójcik B, Loga K, Fichna J, Wiśniewska-Jarosińska M.

World J Gastroenterol. 2014 Jun 14;20(22):7019-26. doi: 10.3748/wjg.v20.i22.7019.

11.

NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease.

Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Chrousos G, Anagnou NP, Roma-Giannikou E.

World J Gastroenterol. 2010 Apr 14;16(14):1753-8.

12.

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.

Barreiro-de Acosta M, Ouburg S, Morré SA, Crusius JB, Lorenzo A, Potel J, Salvador-Peña A, Domínguez-Muñoz JE.

Rev Esp Enferm Dig. 2010 Oct;102(10):591-5.

13.

Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2.

Plantinga TS, Crisan TO, Oosting M, van de Veerdonk FL, de Jong DJ, Philpott DJ, van der Meer JW, Girardin SE, Joosten LA, Netea MG.

Gut. 2011 Sep;60(9):1229-35. doi: 10.1136/gut.2010.228908. Epub 2011 Mar 15.

PMID:
21406388
14.

Monocyte-derived macrophages from Crohn's disease patients are impaired in the ability to control intracellular adherent-invasive Escherichia coli and exhibit disordered cytokine secretion profile.

Vazeille E, Buisson A, Bringer MA, Goutte M, Ouchchane L, Hugot JP, de Vallée A, Barnich N, Bommelaer G, Darfeuille-Michaud A.

J Crohns Colitis. 2015 May;9(5):410-20. doi: 10.1093/ecco-jcc/jjv053. Epub 2015 Mar 24.

PMID:
25805890
15.

IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypes.

Lauriola M, Ugolini G, Rivetti S, Nanì S, Rosati G, Zanotti S, Montroni I, Manaresi A, Zattoni D, Belluzzi A, Castellani L, D'Uva G, Mattei G, Taffurelli M, Strippoli P, Solmi R.

Int J Mol Med. 2011 Mar;27(3):469-77. doi: 10.3892/ijmm.2010.591. Epub 2010 Dec 27.

PMID:
21206965
16.

NOD2, IL23R and ATG16L1 polymorphisms in Lithuanian patients with inflammatory bowel disease.

Sventoraityte J, Zvirbliene A, Franke A, Kwiatkowski R, Kiudelis G, Kupcinskas L, Schreiber S.

World J Gastroenterol. 2010 Jan 21;16(3):359-64.

17.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
18.

A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5.

Prescott NJ, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, Bagnall R, Mirza MM, Sanderson J, Forbes A, Mansfield JC, Lewis CM, Schreiber S, Mathew CG.

Gastroenterology. 2007 May;132(5):1665-71. Epub 2007 Mar 24.

PMID:
17484864
19.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
20.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

Supplemental Content

Support Center